



Denosumab-related osteonecrosis of the jaw after tooth extraction and the effects of a short drug holiday in cancer patients: a multicenter retrospective study

Hasegawa, Takumi ; Ueda, Nobuhiro ; Yamada, Shin-ichi. ; Kato, Shinichiro ; Iwata, Eiji ; Hayashida, Saki ; Kojima, Yuka ; Shinohara, ...

(Citation)

Osteoporosis International, 32(11):2323-2333

(Issue Date)

2021-11

(Resource Type)

journal article

(Version)

Accepted Manuscript

(Rights)

© International Osteoporosis Foundation and National Osteoporosis Foundation 2021. This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature's AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any...

(URL)

<https://hdl.handle.net/20.500.14094/90008798>



Denosumab-related osteonecrosis of the jaw after tooth extraction and the effects of a short drug holiday in cancer patients: A multicenter retrospective study

Takumi Hasegawa, DDS, PhD^{1*}, Nobuhiro Ueda, DDS, PhD^{2‡}, Shin-ichi Yamada, DDS, PhD^{3#}, Shinichiro Kato, DDS, PhD^{4‡}, Eiji Iwata, DDS, PhD^{1,5§}, Saki Hayashida, DDS, PhD^{6‡}, Yuka Kojima, DDS, PhD^{7#}, Mitsuyo Shinohara, DDS, PhD^{8#}, Itaru Tojo, DDS, PhD^{9#}, Hirokazu Nakahara, DDS, PhD^{10**}, Taihei Yamaguchi, DDS, PhD^{11#}, Tadaaki Kirita, DDS, PhD^{2**}, Hiroshi Kurita, DDS, PhD^{3**}, Yasuyuki Shibuya, DDS, PhD^{4**}, Sakiko Soutome, DDS, PhD^{12#}, Masaya Akashi, DDS, PhD^{1**}, and Japanese Study Group of Co-operative Dentistry with Medicine (JCDM)

*Senior Assistant Professor, ‡ Assistant Professor, ^{ll} Senior Assistant Professor, [§] Clinical Fellow, [#] Associate Professor, **Professor and Chairman

¹Department of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine

²Department of Oral and Maxillofacial Surgery, Nara Medical University

³Department of Dentistry and Oral Surgery, Shinshu University School of Medicine

⁴Department of Oral Maxillofacial Surgery, Nagoya City University Graduate School of Medical Sciences

⁵Department of Oral and Maxillofacial Surgery, Kakogawa Central City Hospital

⁶Department of Clinical Oral Oncology, Nagasaki University Graduate School of Biomedical Sciences

⁷Department of Dentistry and Oral Surgery, Kansai Medical University

⁸Department of Oral Maxillofacial Surgery, Juntendo University School of Medicine

⁹Department of Oral and Maxillofacial Surgery, Wakayama Medical University

¹⁰Department of Oral and Maxillofacial Surgery, Osaka City University Graduate School of Medicine

¹¹Department of Preventive Dentistry, Research Field in Dentistry, Medical and Dental Sciences Area, Kagoshima University

¹²Department of Oral Health, Nagasaki University Graduate School of Biomedical Sciences

*Corresponding author: Takumi Hasegawa, DDS, PhD

Department of Oral and Maxillofacial Surgery

Kobe University Graduate School of Medicine

7-5-1, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan

Tel: +81-78-382-6213

Fax: +81-78-351-6229

E-mail: hasetaku@med.kobe-u.ac.jp

Short title: Factors associated with DRONJ after extraction

MINI ABSTRACT

Pre-existing inflammation, corticosteroid therapy, periapical periodontitis, longer duration of denosumab therapy, and female sex were significantly associated with an increased risk of denosumab-related osteonecrosis of the jaw after tooth extraction in patients with cancer on oncologic doses of denosumab. A short drug holiday did not protect against this complication.

ABSTRACT

Purpose

This study retrospectively investigated the relationship between various risk factors, including brief discontinuation of denosumab, and development of denosumab-related osteonecrosis of the jaw (DRONJ) after tooth extraction in patients with cancer who were receiving oncologic doses of this agent.

Methods

Data were collected on demographic characteristics, duration of denosumab therapy, whether or not denosumab was discontinued before tooth extraction (drug holiday), duration of discontinuation, presence of pre-existing inflammation, and whether or not additional surgical procedures were performed. Risk factors for DRONJ after tooth extraction were evaluated by univariate and multivariate analyses.

Results

A total of 136 dental extractions were performed in 72 patients (31 men, 41 women) with cancer who were receiving oncologic doses of denosumab. Post-extraction DRONJ was diagnosed in 39 teeth (28.7%) in 25 patients. Tooth extraction was significantly associated with development of DRONJ only in patients with pre-existing inflammation (odds ratio [OR] 243.77), those on corticosteroid therapy (OR 73.50), those with periapical periodontitis (OR 14.13), those who had been taking oncologic doses of denosumab for a

longer period (OR 4.69), and in women (OR 1.04). There was no significant difference in the occurrence of DRONJ between patients who had a drug holiday before tooth extraction and those who did not.

Conclusions

These findings suggest that inflamed teeth should be extracted immediately in patients with cancer who are receiving oncologic doses of denosumab. Drug holidays have no significant impact on the risk of DRONJ.

Key words: medication-related osteonecrosis of the jaw, denosumab-related osteonecrosis of the jaw, denosumab, discontinuation, drug holiday

1 INTRODUCTION

2 Many patients worldwide are treated with bone-modifying agents (BMAs),
3 including bisphosphonates and denosumab, which act as antiresorptive agents. BMAs
4 suppress bone remodeling and are used to treat osteoporosis, metastatic bone cancer, and
5 multiple myeloma [1, 2]. BMAs have also been used to treat malignancy-induced
6 hypercalcemia and to reduce the risk of skeletal-related events [3, 4]. Since the first reports
7 of bisphosphonate-related osteonecrosis of the jaw by Marx et al and Migliorati et al,
8 medication-related osteonecrosis of the jaw (MRONJ) induced by bisphosphonates and
9 denosumab has become widely recognized [5, 6, 7].

10 The MRONJ position paper published by the American Association of Oral and
11 Maxillofacial Surgeons (AAOMS) acknowledged that tooth extraction was a major trigger
12 for MRONJ, with 52%–61% of patients reporting tooth extraction as the precipitating event
13 [1]. The incidence rate of MRONJ after tooth extraction in patients with osteoporosis is
14 0.09%–2.8% [8-10], and the risk is higher in patients with cancer who receive cumulative
15 doses of BMAs approximately 10–12 times those administered for osteoporosis [1, 2].
16 Although tooth extraction itself is the main risk factor for MRONJ, excessive delay in
17 extracting an inflamed tooth also increases the risk of MRONJ [11]. We have previously
18 demonstrated that pre-existing inflammation is a more important risk factor for MRONJ in
19 patients on oncologic doses of BMAs than tooth extraction per se [12]. Moreover, there is
20 doubt about the effectiveness of a short-term drug holiday, given that the available evidence
21 suggests that drug holidays have no significant impact on the incidence of MRONJ [10,
22 12].

23 Denosumab has been found to be more effective than bisphosphonates in terms of
24 increasing bone mineral density in patients with osteoporosis [13] and suppressing bone
25 remodeling in those with cancer [14]. Denosumab can be used more safely than
26 bisphosphonates in patients with impaired renal function [15]. Furthermore, denosumab
27 does not accumulate in bone tissue and has a considerably shorter half-life than the

1 bisphosphonates (28 days vs 10–12 years) [16]. Clinically, there have been cases where the
2 monthly dose of denosumab was skipped before tooth extraction. However, there is no
3 evidence to suggest that a drug holiday reduces the risk of denosumab-related osteonecrosis
4 of the jaw (DRONJ) or prevents it after tooth extraction. Moreover, no study has
5 comprehensively analyzed the influence of a drug holiday and other potential risk factors,
6 such as pre-existing inflammation and surgery-related factors, on the incidence of DRONJ
7 after dental extraction in patients on denosumab. We hypothesized that pre-existing
8 inflammation and surgery-related factors, including primary wound closure, would
9 influence the risk of DRONJ. In this study, we investigated the relationships between the
10 various putative risk factors for DRONJ after tooth extraction in patients with cancer on
11 oncologic doses of denosumab.

12

13

1 **METHODS**

2 This multicenter nonrandomized retrospective cohort validation study included
3 pooled data for patients from ten institutions that are members of the Japanese Study Group
4 of Co-operative Dentistry with Medicine. A total of 168 patients who were receiving
5 denosumab therapy underwent tooth extraction at these institutions between January 2008
6 and December 2019. Two hundred and eleven extractions were performed in 96 patients
7 receiving denosumab for osteoporosis. Post-extraction DRONJ was diagnosed in three
8 teeth (1.4%) in three patients (3.1%). Patients with osteoporosis were excluded from the
9 study because the number of events was too small for analysis of the study variables.
10 Finally, 136 dental extractions performed in 72 patients (31 men, 41 women) with cancer
11 and receiving an oncologic (120 mg) dose of denosumab once a month were included in the
12 study. The mean patient age was 65.2 ± 11.8 (range, 41–85) years.

13 The study was approved by the institutional review board of Kobe University
14 Graduate School of Medicine and by the institutional review boards of the other
15 participating hospitals (authorization number: 190273). All patients consented to treatment
16 after being informed about MRONJ and other extraction-associated risks. The definition of
17 MRONJ was taken from the position paper published by the AAOMS [1]. For a diagnosis
18 of MRONJ, the following three criteria should be met: 1) current or previous treatment
19 with antiresorptive or antiangiogenic agents; 2) exposed bone or bone that can be probed
20 through an intraoral or extraoral fistula in the maxillofacial region and has persisted for
21 longer than 8 weeks; and 3) no history of radiation therapy to the jaw or obvious metastatic
22 disease of the jaw. The demographics and clinical characteristics of all patients were
23 investigated, including duration of oncologic doses of denosumab, whether or not
24 denosumab was discontinued for 30 days before tooth extraction (i.e., a drug holiday),
25 additional surgical procedures such as incision, bone removal, tension-relieving incision,
26 root amputation, and suturing, whether antibiotics were administered before extraction,
27 pre-existing inflammation, bone loss around the tooth, duration of follow-up, and time until

1 primary wound healing without evidence of infection. The definition of discontinuation
2 was a drug holiday of more than one month (30 days) before extraction. Pre-existing
3 inflammation was defined as clinical symptoms (pain, swelling, redness, or purulent
4 discharge) requiring administration of antibiotics within the 2 weeks before extraction. As a
5 practical matter, the majority of inflamed teeth designated for extraction are infected. The
6 reason for extraction, number of teeth extracted, and site of extraction were also
7 investigated. Alveolar bone loss was measured at the mesial and distal surfaces of the tooth
8 between the apex of the root and the cervical margin using orthopantomography. Bone loss
9 around a tooth was defined as $(\text{average [medial and distal] length}) / (\text{distance between root}$
10 $\text{apex and cervical margin}) \times 100 \geq 50\%$ and a tooth with alveolar bone loss of more than
11 two-thirds of the root and a probing depth of more than 6 mm was defined as P4
12 periodontitis. A tooth with caries reaching the tooth roots or a residual root stump was
13 defined as C4 caries. The data were entered into a multiple logistic regression model in
14 which patients were divided according to number of teeth extracted (single vs multiple),
15 wound status (open vs closed), type of cancer (breast vs non-breast and prostate vs
16 non-prostate), and Eastern Cooperative Oncology Group performance status (0 or 1 vs 2 or
17 3) [17]. The primary outcome was the occurrence of DRONJ. Possible development of
18 DRONJ was noted and, if present, classified according to stage, in line with the AAOMS
19 position paper (stage 0, no clinical evidence of necrotic bone, with nonspecific clinical
20 findings, radiographic changes, and symptoms; stage 1, exposed and necrotic bone or
21 fistulas that probe to bone in patients who are asymptomatic, no evidence of infection;
22 stage 2, exposed and necrotic bone or fistulas that probe to bone, associated with infection
23 as evidenced by pain and erythema in the region of exposed bone, with or without purulent
24 drainage; and stage 3, exposed and necrotic bone or a fistula that probes to bone in patients
25 with pain, infection, and more than one of the following: exposed and necrotic bone
26 extending beyond the region of alveolar bone [i.e., inferior border and ramus of the
27 mandible, maxillary sinus, and zygoma in the maxilla] resulting in pathologic fracture,

1 extraoral fistula, oral antral or oral nasal communication, or osteolysis extending to the
2 inferior border of the mandible or the sinus floor) [1].

3 **Statistical analysis**

4 The statistical analyses were performed using SPSS version 22.0 (IBM Corp.,
5 Armonk, NY, USA) and Ekuseru-Toukei 2012 software (Social Survey Research
6 Information Co., Ltd., Tokyo, Japan). The association of each variable with DRONJ was
7 analyzed using the Mann-Whitney *U* nonparametric test for ordinal variables and with
8 Fisher's exact test or the chi-squared test for categorical variables. A p-value <0.05 was
9 accepted as statistically significant. Smoking history was excluded from multivariate
10 analysis because it was not a significant risk factor in univariate analysis and the data
11 needed were incomplete. The remainder of the variables were introduced into a multiple
12 logistic regression model. Forward stepwise algorithms were used; variables that did not fit
13 the model significantly were rejected. Odds ratios (ORs) and 95% confidence intervals
14 (CIs) were calculated. The cumulative incidence rate of DRONJ was calculated using the
15 Kaplan-Meier product limit method.

16 The discriminatory ability of the duration of administration of oncologic doses of
17 denosumab as an indicator of possible DRONJ was evaluated by receiver-operating
18 characteristic (ROC) curve analysis. The ROC curve was used to determine the cutoff
19 values for clinical tests. The area under the ROC curve measures the accuracy of
20 discrimination (range, 0.5 to 1). The cutoff value was chosen to minimize the number of
21 false-positive and false-negative results.

22

23

24

1 RESULTS

2 The patient demographics and clinical characteristics are shown in Tables 1 and 2.
3 The cumulative incidence rates of DRONJ at 6, 12, 18, and 24 months were 4.6%, 7.7%,
4 17.6%, and 34.3%, respectively (Figure 1). There was no significant difference in the
5 incidence of DRONJ according to age, sex, smoking history, or performance status. The
6 duration of oncologic doses of denosumab was significantly longer in patients who
7 developed DRONJ than in those who did not ($p < 0.001$; Table 1 and 2). There was a
8 significant difference in the incidence of DRONJ between patients treated with oncologic
9 doses of denosumab for ≥ 18 months and those treated for < 18 months. The time interval
10 between the most recent dose of denosumab and tooth extraction was longer in patients
11 who developed DRONJ than in those who did not (Tables 1 and 2); however, differences in
12 the incidence of DRONJ were not significantly different between patients on corticosteroid
13 therapy, those with diabetes mellitus, those with other drug-induced risk factors, and those
14 who had a drug holiday before tooth extraction and patients without these factors in
15 univariate analysis (Tables 1 and 2). Periapical periodontitis was a significant predictor of
16 DRONJ ($p = 0.014$; Table 2). However, there was no significant difference in the likelihood
17 of development of DRONJ according to site of extraction (anterior vs posterior region or
18 maxillary vs mandibular), bone volume around the tooth, or number of teeth extracted.
19 Extraction of a tooth with pre-existing inflammation was a significant predictor of DRONJ
20 ($p < 0.001$; Tables 1 and 2). Procedure-related factors, such as bone removal, root
21 amputation, and wound status, were not significant risk factors. DRONJ was less likely to
22 develop in patients who had complete wound closure with tension-relieving incisions
23 and/or removal of bone edges; however, the difference was not statistically significant.

24 Applying a logistic regression model and forward stepwise algorithms, we found
25 significant associations of DRONJ with tooth extraction in patients with pre-existing
26 inflammation (OR 243.77), those on corticosteroid therapy (OR 73.50), those with
27 periapical periodontitis (OR 14.13), those on oncologic doses of denosumab for a longer

1 period (OR 4.69), and women (OR 1.04; Table 3).

2 The area under the ROC curve was 0.71. Maximization of the harmonic mean of
3 specificity and sensitivity put the cutoff value for duration of oncologic doses of
4 denosumab for predicting post-extraction DRONJ at 18 months (Figure 2). The sensitivity
5 was 0.72 and the specificity was 0.69.

6

7

8

1 **DISCUSSION**

2 The incidence rate of DRONJ was 0%–11.4% in several studies performed in
3 patients with solid tumors and bone metastasis [18-22]. In a systematic review and
4 meta-analysis of MRONJ in patients with cancer, the incidence rate of DRONJ ranged from
5 0.5% to 2.1% after 1 year, 1.1% to 3.0% after 2 years, and 1.3% to 3.2% after 3 years of
6 exposure [23]. However, the incidence rate of DRONJ in patients undergoing tooth
7 extraction has been very high (14.3%–31.6%) [24, 25]. In the present study, the incidence
8 rate of DRONJ after tooth extraction was 28.7%, which is similar to that in the previous
9 studies. However, it may be difficult to distinguish stage 0 MRONJ from tooth infection,
10 and it is possible that our cases of DRONJ included patients who had already developed
11 MRONJ before tooth extraction. Pre-existing inflammatory dental disease causes MRONJ
12 in 50% of patients with cancer [26, 27]. In our study, 97.4% of all patients who developed
13 DRONJ had pre-existing inflammation. Soutome et al investigated factors related to
14 development of MRONJ in patients with cancer who had received oncologic doses of
15 bisphosphonates or denosumab and concluded that the factors putting patients at increased
16 risk of MRONJ were the underlying infection and not the extraction itself [28]. Other
17 investigators have reported that extraction of noninflamed ankylosed primary teeth in
18 bisphosphonate-treated children with osteogenesis imperfecta rarely, if ever, leads to
19 MRONJ [29, 30]. In our study, multivariate analysis identified pre-existing inflammation
20 (OR 243.77) and periapical periodontitis (OR 14.13) to be significant risk factors for
21 MRONJ, as in other studies [22, 24, 28]. Therefore, patients with fractured or extensively
22 caries-damaged and unrestorable teeth without active periodontal or periapical
23 inflammation may be at low risk of DRONJ after extraction.

24 Corticosteroids and immunosuppressant therapy delay postoperative wound
25 healing [31-34]. Corticosteroids reduce angiogenesis and the activity of various cells,
26 including osteoclasts and osteoblasts [33-35]; these cells are induced into early apoptosis,
27 which decreases bone turnover [34]. Avascular osteonecrosis of the femur and vertebra has

1 been reported [33, 34]. In a study by Aljohani et al, 11.1% of 63 patients with MRONJ
2 were receiving long-term corticosteroid therapy [36]. There has also been a case report of a
3 non-healing socket after tooth extraction in a patient who had been receiving long-term
4 corticosteroid therapy without any other MRONJ-causing agent [37]. In the present study,
5 multivariate analysis identified corticosteroid therapy (OR 73.50) to be a significant risk
6 factor for DRONJ.

7 The majority of oncology patients who develop DRONJ have either prostate
8 cancer or breast cancer [19, 20, 22-24]. Breast cancer was the most common type of cancer
9 in patients with DRONJ in our study, which is consistent with other reports [22, 36, 38].
10 Although women have not been confirmed to be at higher risk for DRONJ, we identified
11 female sex to be a significant risk factor in multivariate analysis, although the OR was low
12 (1.04). This finding may reflect the female-specific nature of particular cancers, such as
13 those affecting the breast or reproductive system.

14 Theoretically, long-term treatment with bisphosphonates carries a high risk of
15 MRONJ. However, given that denosumab does not accumulate in bone tissue and has a
16 short half-life, it is controversial as to whether or not the cumulative dose of denosumab
17 affects the risk of development of MRONJ in the same way as that of a bisphosphonate.
18 Saad et al reported that the incidence of MRONJ was 0.5%–0.8% at 1 year and 1.0%–1.8%
19 at 2–3 years in patients with cancer receiving zoledronate or denosumab [26]. In their study,
20 the median duration of drug exposure before diagnosis of MRONJ was 14 months in both
21 treatment groups. Juras et al reported an increase in the incidence rate of DRONJ with
22 increasing duration of follow-up in patients with cancer on denosumab therapy (3% at 1
23 year, 7% at 2 years, and 8% beyond 30 months). In our present study, the cumulative
24 incidence rates of DRONJ at 6, 12, 18, and 24 months were 4.6%, 7.7%, 17.6%, and 34.3%,
25 respectively. Moreover, in multivariate analysis, we found a longer duration of oncologic
26 doses of denosumab to be a significant risk factor for DRONJ (OR 4.69).

27 Physicians should refer all patients who are on oncologic doses of denosumab for

1 an immediate oral examination and treatment planning by a dental professional familiar
2 with DRONJ. Tooth extraction in patients taking oncologic doses of denosumab is less
3 likely to lead to DRONJ when the duration of denosumab therapy has been less than 18
4 months. Therefore, teeth that are not salvageable or have a poor prognosis should be
5 extracted as soon as possible, preferably before the start of denosumab therapy. Our data
6 indicate that inflamed teeth should be extracted immediately in oncology patients who are
7 taking denosumab, especially those with breast or prostate cancer and a favorable
8 prognosis.

9 Theoretically, tooth extraction should be performed in patients with cancer without
10 discontinuation of oncologic doses of a BMA, given that they are needed for management
11 of skeletal-related events. We recently reported that a short (2-month) drug holiday from
12 oral bisphosphonates before tooth extraction did not reduce the incidence of MRONJ in
13 patients with osteoporosis [10]. Similarly, a short drug holiday from oncologic doses of a
14 BMA before tooth extraction did not reduce the incidence of MRONJ in patients with
15 cancer [12]. Denosumab does not accumulate in bone tissue and its elimination half-life (28
16 days) is much shorter than that of the bisphosphonates [16]. However, its
17 pharmacodynamic half-life, that is, the duration of its antiresorptive effect, is longer than its
18 elimination half-life [39, 40]. In a study by Bone et al, the time to full reversal of the
19 antiresorptive effects of a 60 mg dose of denosumab for osteoporosis was 9 months [39].
20 As with the 60 mg dose, the antiresorptive effects of a 120 mg dose of denosumab may be
21 at least 9 months after the last dose in oncology patients, although there is as yet no
22 supporting evidence for this. Several investigators have demonstrated the effectiveness of a
23 1-2 year drug holiday from denosumab in the treatment of MRONJ [41, 42]. However, in
24 most oncology patients, denosumab is a life-prolonging medication that cannot be
25 discontinued for such a long period. Others have concluded that a drug holiday has no
26 effect on the healing outcome in patients with MRONJ [36, 38, 43]. In this study, we could
27 not confirm the effectiveness of a short drug holiday before tooth extraction, which

1 indicates that drug holidays are likely to have no significant impact on the incidence of
2 MRONJ. Demographic features and local factors, such as pre-existing inflammation,
3 appear to be more important risk factors for DRONJ than continuation of oncologic doses
4 of denosumab before or after tooth extraction. Moreover, in patients with osteoporosis,
5 discontinuation of 6-monthly injections of denosumab resulted in a rebound increase in
6 bone resorption, rapid bone loss, and clusters of fractures after 9–12 months [44]. Therefore,
7 denosumab should not be delayed or stopped before tooth extraction.

8 This study was limited by its retrospective non-matched design, which meant that
9 other risk factors, such as indices of oral hygiene, could not be examined. Although
10 multivariate analysis was performed to decrease the effect of confounding factors as far as
11 possible, the possibility of selection bias could not be completely excluded. A large-scale,
12 prospective cohort study is needed to evaluate predictors of DRONJ in patients with cancer
13 who are on denosumab.

14 In conclusion, we have successfully demonstrated relationships between various
15 risk factors and DRONJ after tooth extraction in patients with cancer who are receiving
16 oncologic doses of denosumab. Pre-existing inflammation, corticosteroid therapy,
17 extraction of teeth with periapical periodontitis, longer duration of oncologic doses of
18 denosumab, and female sex were significantly associated with development of DRONJ.
19 These findings suggest that inflamed teeth should be extracted immediately in patients with
20 cancer who are receiving oncologic doses of denosumab. DRONJ is more likely to occur in
21 patients with cancer who have taken denosumab for longer than 18 months than in those
22 who have taken it for a shorter period. Drug holidays for less than 9 months have no
23 significant impact on the risk of DRONJ.

24

25 **Conflicts of interest:** Takumi Hasegawa, Nobuhiro Ueda, Shin-ichi Yamada, Shinichiro
26 Kato, Eiji Iwata, Saki Hayashida, Yuka Kojima, Mitsuyo Shinohara, Itaru Tojo, Hirokazu
27 Nakahara, Taihei Yamaguchi, Tadaaki Kirita, Hiroshi Kurita, Yasuyuki Shibuya, Sakiko

1 Soutome, and Masaya Akashi declare that they have no conflicts of interest.

2

3

4

5

1 REFERENCES

- 2 [1] Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O’Ryan F;
3 American Association of Oral and Maxillofacial Surgeons (2014) American
4 Association of Oral and Maxillofacial Surgeons position paper on medication-related
5 osteonecrosis of the jaw--2014 update. *J Oral Maxillofac Surg* 72:1938–1956.
- 6 [2] Otto S, Pautke C, Van den Wyngaert T, Niepel D, Schiødt M (2018) Medication-related
7 osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer
8 and bone metastases. *Cancer Treat Rev* 69:177-187.
- 9 [3] Berenson JR, Rajdev L, Broder M (2006) Treatment strategies for skeletal
10 complications of cancer. *Cancer Biol Ther* 5:1074-1077.
- 11 [4] Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N,
12 Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) Denosumab versus
13 zoledronic acid for treatment of bone metastases in men with castration-resistant
14 prostate cancer: a randomised, double-blind study. *Lancet* 377:813-822.
- 15 [5] Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular
16 necrosis of the jaws: a growing epidemic. *J Oral Maxillofac Surg* 61:1115–1117.
- 17 [6] Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. *J Clin Oncol.*
18 2003;21(22):4253-4.
- 19 [7] Yoshimura H, Ohba S, Yoshida H, Saito K, Inui K, Yasui R, Ichikawa D, Aiki M,
20 Kobayashi J, Matsuda S, Imamura Y, Sano K (2017) Denosumab-related osteonecrosis
21 of the jaw in a patient with bone metastases of prostate cancer: A case report and
22 literature review. *Oncol Lett* 14:127-136.
- 23 [8] Mavrokokki T, Cheng A, Stein B, Goss A (2007) Nature and frequency of
24 bisphosphonate-associated osteonecrosis of the jaws in Australia. *J Oral Maxillofac*
25 *Surg* 65:415–423
- 26 [9] Kunchur R, Need A, Hughes T, Goss A (2009) Clinical investigation of C-terminal
27 cross-linking telopeptide test in prevention and management of

- 1 bisphosphonate-associated osteonecrosis of the jaws. *J Oral Maxillofac Surg* 67:1167.
- 2 [10] Hasegawa T, Kawakita A, Ueda N, Funahara R, Tachibana A, Kobayashi M, Kondou E,
3 Takeda D, Kojima Y, Sato S, Yanamoto S, Komatsubara H, Umeda M, Kirita T, Kurita
4 H, Shibuya Y, Komori T; Japanese Study Group of Cooperative Dentistry with Medicine
5 (JCDM) (2017) A multicenter retrospective study of the risk factors associated with
6 medication-related osteonecrosis of the jaw after tooth extraction in patients receiving
7 oral bisphosphonate therapy: can primary wound closure and a drug holiday really
8 prevent MRONJ? *Osteoporos Int* 28:2465-2473.
- 9 [11] Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh
10 G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN (2008)
11 Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients
12 treated with intravenous bisphosphonates. *J Bone Miner Res* 23:826–836.
- 13 [12] Hasegawa T, Hayashida S, Kondo E, Takeda Y, Miyamoto H, Kawaoka Y, Ueda N,
14 Iwata E, Nakahara H, Kobayashi M, Soutome S, Yamada SI, Tojyo I, Kojima Y, Umeda
15 M, Fujita S, Kurita H, Shibuya Y, Kirita T, Komori T; Japanese Study Group of
16 Co-operative Dentistry with Medicine (JCDM) (2019) Medication-related osteonecrosis
17 of the jaw after tooth extraction in cancer patients: a multicenter retrospective study.
18 *Osteoporos Int* 30(1):231-239.
- 19 [13] Brown JP, Fortier M, Frame H, Lalonde A, Papaioannou A, Senikas V, Yuen CK;
20 Osteoporosis Guidelines Committee (2006) Canadian Consensus Conference on
21 osteoporosis, 2006 update. *J Obstet Gynaecol Can* 28(2 Suppl 1):S95-112.
- 22 [14] Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, de Boer R,
23 Berardi R, Gascon P, Tonkin KS, Coleman RE, Paterson AH, Gao GM, Kinsey AC,
24 Peterson MC, Jun S (2008) Extended efficacy and safety of denosumab in breast
25 cancer patients with bone metastases not receiving prior bisphosphonate therapy. *Clin*
26 *Cancer Res* 14(20):6690-6.
- 27 [15] Anastasilakis AD, Toulis KA, Polyzos SA, Anastasilakis CD, Makras P (2012)

- 1 Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab. *Ther*
2 *Clin Risk Manag* 8:295-306.
- 3 [16] Amgen, Inc. Prolia (denosumab) prescribing information. 2010 updated 2014.
- 4 [17] Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP
5 (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am*
6 *J Clin Oncol* 5(6):649-655.
- 7 [18] Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, Gao G, Wu L, Sohn W,
8 Jun S (2009) Randomized phase II trial of denosumab in patients with bone metastases
9 from prostate cancer, breast cancer, or other neoplasms after intravenous
10 bisphosphonates. *J Clin Oncol* 27(10):1564-71.
- 11 [19] Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, de Boer R,
12 Berardi R, Gascon P, Tonkin KS, Coleman R, Paterson AH, Peterson MC, Fan M,
13 Kinsey A, Jun S (2007) Randomized active-controlled phase II study of denosumab
14 efficacy and safety in patients with breast cancer-related bone metastases. *J Clin Oncol*
15 25(28):4431-7.
- 16 [20] Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, Heracek
17 J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C; Denosumab HALT Prostate
18 Cancer Study Group (2009) Denosumab in men receiving androgen-deprivation therapy
19 for prostate cancer. *N Engl J Med* 361(8):745-55.
- 20 [21] Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P,
21 Karsh L, Damião R, Tammela TL, Egerdie B, Van Poppel H, Chin J, Morote J,
22 Gómez-Veiga F, Borkowski T, Ye Z, Kupic A, Dansey R, Goessl C (2012) Denosumab
23 and bone-metastasis-free survival in men with castration-resistant prostate cancer:
24 results of a phase 3, randomised, placebo-controlled trial. *Lancet* 379(9810):39-46.
- 25 [22] Okuma S, Matsuda Y, Nariai Y, Karino M, Suzuki R, Kanno T (2020) A
26 Retrospective Observational Study of Risk Factors for Denosumab-Related
27 Osteonecrosis of the Jaw in Patients with Bone Metastases from Solid Cancers. *Cancers*

- 1 (Basel) 12(5):1209.
- 2 [23] Limones A, Sáez-Alcaide LM, Díaz-Parreño SA, Helm A, Bornstein MM,
3 Molinero-Mourelle P (2020) Medication-related osteonecrosis of the jaws (MRONJ) in
4 cancer patients treated with denosumab VS. zoledronic acid: A systematic review and
5 meta-analysis. *Med Oral Patol Oral Cir Bucal* 25(3):e326-e336.
- 6 [24] Ueda N, Nakashima C, Aoki K, Shimotsuji H, Nakaue K, Yoshioka H, Kurokawa S,
7 Imai Y, Kirita T (2020) Does inflammatory dental disease affect the development of
8 medication-related osteonecrosis of the jaw in patients using high-dose bone-modifying
9 agents? *Clin Oral Investig* [Online ahead of print].
- 10 [25] Matsumoto A, Sasaki M, Schmelzeisen R, Oyama Y, Mori Y, Voss PJ (2017) Primary
11 wound closure after tooth extraction for prevention of medication-related osteonecrosis
12 of the jaw in patients under denosumab. *Clin Oral Investig* 21(1):127-134.
- 13 [26] Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, Diel IJ,
14 Takahashi S, Shore N, Henry DH, Barrios CH, Facon T, Senecal F, Fizazi K, Zhou L,
15 Daniels A, Carrière P, Dansey R (2012) Incidence, risk factors, and outcomes of
16 osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase
17 III trials in cancer patients with bone metastases. *Ann Oncol* 23:1341-1347.
- 18 [27] Yamazaki T, Yamori M, Ishizaki T, Asai K, Goto K, Takahashi K, Nakayama T, Bessho
19 K (2012) Increased incidence of osteonecrosis of the jaw after tooth extraction in
20 patients treated with bisphosphonates: a cohort study. *Int J Oral Maxillofac Surg*
21 41:1397-1403.
- 22 [28] Soutome S, Hayashida S, Funahara M, Sakamoto Y, Kojima Y, Yanamoto S, Umeda M
23 (2018) Factors affecting development of medication-related osteonecrosis of the jaw in
24 cancer patients receiving high-dose bisphosphonate or denosumab therapy: Is tooth
25 extraction a risk factor? *PLoS One* 13(7):e0201343.
- 26 [29] Schwartz S, Joseph C, Iera D, Vu DD (2008) Bisphosphonates, osteonecrosis,
27 osteogenesis imperfecta and dental extractions: a case series. *J Can Dent Assoc*

- 1 74(6):537-42.
- 2 [30] Chahine C, Cheung MS, Head TW, Schwartz S, Glorieux FH, Rauch F (2008) Tooth
3 extraction socket healing in pediatric patients treated with intravenous pamidronate. *J*
4 *Pediatr* 153(5):719-20.
- 5 [31] Guilbeau, J.M. (2002) Delayed wound healing with sirolimus after liver transplant.
6 *Ann Pharmacother.* 2002 Sep;36(9):1391-5.
- 7 [32] Cavalli RC, Tambara Filho R, Gomes Rde P, Veronez DA, Slongo J, Fraga Rd (2014)
8 Analysis of the histology of the scar bladder and biochemical parameters of rats with a
9 solitary kidney undergoing immunosuppression with tacrolimus. *Acta Cir Bras*
10 29(8):508-14.
- 11 [33] Weinstein RS (2012) Glucocorticoid-induced osteonecrosis. *Endocrine* 41(2):183-90.
- 12 [34] Weinstein RS (2012) Glucocorticoid-induced osteoporosis and osteonecrosis.
13 *Endocrinol Metab Clin North Am* 41(3):595-611.
- 14 [35] Takano-Murakami R, Tokunaga K, Kondo N, Ito T, Kitahara H, Ito M, Endo N (2009)
15 Glucocorticoid inhibits bone regeneration after osteonecrosis of the femoral head in
16 aged female rats. *Tohoku J Exp Med* 217(1):51-8.
- 17 [36] Aljohani S, Gaudin R, Weiser J, Tröltzsch M, Ehrenfeld M, Kaeppler G, Smeets R,
18 Otto S (2018) Osteonecrosis of the jaw in patients treated with denosumab: A
19 multicenter case series. *J Craniomaxillofac Surg* 46(9):1515-1525.
- 20 [37] Wong LS, Tay KK, Cheing YL (2015) Osteonecrosis of mandible: a rare complication
21 of long-term steroid use. *J Oral Maxillofac Surg Med Pathol* 27:255-257.
- 22 [38] Hoefert S, Yuan A, Munz A, Grimm M, Elayouti A, Reinert S (2017) Clinical course
23 and therapeutic outcomes of operatively and non-operatively managed patients with
24 denosumab-related osteonecrosis of the jaw (DRONJ). *J Craniomaxillofac Surg*
25 45(4):570-578.
- 26 [39] Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, Grazette L,
27 San Martin J, Gallagher JC (2011) Effects of denosumab treatment and discontinuation

- 1 on BMD and bone turnover markers in postmenopausal women with low bone mass. *J*
2 *Clin Endocrinol Metab* 96(4):972-80.
- 3 [40] Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, Liu Y,
4 San Martin J; Amg Bone Loss Study Group (2008) Effect of denosumab on BMD and
5 turnover in postmenopausal women with low bone mass after long-term continued,
6 discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial.
7 *Bone* 43(2):222-9.
- 8 [41] Malan J, Ettinger K, Naumann E, Beirne OR (2012) The relationship of denosumab
9 pharmacology and osteonecrosis of the jaws. *Oral Surg Oral Med Oral Pathol Oral*
10 *Radiol* 114(6):671-6.
- 11 [42] Taylor KH, Middlefell LS, Mizen KD (2010) Osteonecrosis of the jaws induced by
12 anti-RANK ligand therapy. *Br J Oral Maxillofac Surg* 48(3):221-3.
- 13 [43] Hayashida S, Yanamoto S, Fujita S, Hasegawa T, Komori T, Kojima Y, Miyamoto H,
14 Shibuya Y, Ueda N, Kirita T, Nakahara H, Shinohara M, Kondo E, Kurita H, Umeda
15 M (2020) Drug holiday clinical relevance verification for antiresorptive agents in
16 medication-related osteonecrosis cases of the jaw. *J Bone Miner Metab* 38(1):126-134.
- 17 [44] McClung MR (2016) Cancel the denosumab holiday. *Osteoporos Int* 27(5):1677-82.
18
19
20

1 **TABLE AND FIGURE CAPTIONS**

2

3 Tab.1 Characteristics of patients according to whether or not denosumab-related
4 osteonecrosis of the jaw was present

5

6 Tab. 2 Characteristics of extracted teeth according to whether or not denosumab-related
7 osteonecrosis of the jaw was present

8

9 Tab. 3 Results of multivariate logistic regression analysis of risk factors for
10 denosumab-related osteonecrosis of the jaw

11

12 Fig. 1 Cumulative incidence rate of denosumab-related osteonecrosis of the jaw in patients
13 with cancer on denosumab therapy.

14

15 Fig. 2 Receiver-operating characteristic curve for duration of administration of denosumab
16 as an indicator of possible denosumab-related osteonecrosis of the jaw.

17

18 **ACKNOWLEDGEMENTS**

19 We thank Editage (<https://www.editage.jp/>) for editing a draft of this manuscript.

20

21

Table 1. Characteristics of patients according to whether or not denosumab-related osteonecrosis of the jaw was present

Variable	DRONJ		P-value
	Present n (%)	Absent n (%)	
Patients, n	25 (34.7)	47 (65.3)	
Stage 0	1 (4.0)	-	
Stage 1	10 (40.0)	-	
Stage 2	11 (44.0)	-	
Stage 3	3 (12.0)	-	
Sex			
Male	10 (40.0)	21 (43.1)	0.805 *
Female	15 (60.0)	26 (56.9)	
Age			
Range (years)	44–82	41–85	
Mean \pm SD	66.3 \pm 11.3	64.60 \pm 12.2	0.534 **
Performance status			
0 or 1	23 (92.0)	44 (93.6)	1.000 *
2 or 3	2 (8.0)	3 (6.4)	
Smoking history			
Yes	3 (12.0)	9 (19.1)	0.735*
No	18 (72.0)	33 (70.2)	
Unknown	4 (16.0)	5 (10.6)	
Duration of oncologic doses of denosumab			
Range (months)	5–51	1–85	
Mean \pm SD	22.4 \pm 13.5	13.7 \pm 15.3	< 0.001**
\geq 18 months	16 (66.7)	10 (27.8)	< 0.001*
< 18 months	9 (33.3)	37 (72.2)	
Comorbidity or drug-induced risk factors			
Diabetes mellitus			
Yes	2 (8.0)	3 (6.4)	1.000*
No	23 (92.0)	44 (93.6)	
Corticosteroid therapy			
Yes	4 (16.0)	8 (17.0)	1.000*
No	21 (84.0)	39 (83.0)	
Additional chemotherapy			

Yes	17 (72.3)	34 (70.8)	0.787*
No	8 (27.7)	13 (28.2)	
Type of cancer			
Breast cancer	8 (32.0)	12 (25.5)	0.171***
Prostate cancer	2 (8.0)	12 (25.5)	
Multiple myeloma	1 (4.0)	4 (8.5)	
Lung cancer	2 (8.0)	6 (12.8)	
Other	1 (4.0)	4 (8.5)	
Unknown	11 (44.0)	9 (19.1)	
Interval between tooth extraction and last denosumab injection			
Range (days)	1–283	2–272	
Mean ± SD	66.0 ± 61.7	58.9 ± 63.5	0.367**
Drug holiday before tooth extraction			
Yes	18 (46.2)	54 (55.7)	0.347*
No	21 (53.8)	43 (44.3)	
Reason for tooth extraction			
Periapical periodontitis			
Yes	16 (64.0)	25 (56.9)	0.457*
No	9 (36.0)	22 (43.1)	
P4 periodontitis			
Yes	3 (12.0)	10 (21.3)	0.521*
No	22 (88.0)	37 (78.7)	
Pericoronitis			
Yes	4 (16.0)	2 (4.6)	0.173*
No	21 (84.0)	45 (95.7)	
Jawbone			
Maxillary	10 (40.0)	23 (48.9)	0.881***
Mandibular	14 (56.0)	21 (44.7)	
Maxillary and mandibular	1 (4.0)	3 (6.4)	
Site of tooth extraction			
Anterior region	2 (8.0)	5 (10.6)	0.562***
Molar region	22 (88.0)	37 (78.7)	
Anterior and molar region	1 (4.0)	5 (10.6)	
Bone volume around tooth			
Adequate alveolar bone volume	19 (76.0)	31 (66.0)	0.432*
Bone loss	6 (24.0)	16 (44.0)	
Pre-existing inflammation			
Yes	24 (96.0)	29 (61.7)	0.002*

No	1 (4.0)	18 (38.3)	
Preoperative antibiotics administration			
Yes	24 (61.5)	51 (52.6)	0.446*
No	15 (38.5)	46 (47.4)	
Number of teeth extracted			
Single	11 (44.0)	20 (42.6)	1.000*
Multiple	14 (56.0)	27 (57.4)	
Additional surgical procedure			
Bone removal			
Yes	11 (44.0)	11 (23.4)	0.106*
No	14 (56.0)	36 (76.6)	
Root amputation			
Yes	5 (20.0)	6 (12.8)	0.497*
No	20 (80.0)	41 (87.2)	
Wound status after extraction			
Open	12 (48.0)	15 (31.9)	0.736***
Closed with suture	12 (48.0)	28 (59.6)	
Completely closed with relaxation incision or removal of bone edge	1 (4.0)	4 (8.5)	

*Fisher's exact test, **Mann-Whitney *U* test, ***chi-squared test. DRONJ, denosumab-related osteonecrosis of the jaw; SD, standard deviation

Table 2. Characteristics of extracted teeth according to whether or not denosumab-related osteonecrosis of the jaw was present

Variable	DRONJ		P-value
	Present n (%)	Absent n (%)	
Teeth, n	39 (28.7)	97 (71.3)	
Sex			
Male	16 (41.0)	47 (48.5)	0.454*
Female	23 (59.0)	50 (51.5)	
Age			
Range (years)	44–82	41–85	
Mean ± SD	66.6 ± 10.0	66.0 ± 13.0	0.860**
Performance status			
0 or 1	36 (92/3)	87 (89.7)	0.355*
2 or 3	3 (7.7)	10 (10.3)	
Duration of oncologic doses of denosumab			
Range (months)	5–51	1–85	
Mean ± SD	23.4 ± 13.1	15.7 ± 14.0	< 0.001**
≥18 months	26 (66.7)	27 (27.8)	< 0.001*
<18 months	13 (33.3)	70 (72.2)	
Comorbidity or drug-induced risk factors			
Diabetes mellitus			
Yes	2 (5.1)	16 (6.2)	1.000*
No	37 (94.9)	91 (93.8)	
Corticosteroid therapy			
Yes	9 (23.1)	13 (13.4)	0.200*
No	30 (76.9)	84 (86.6)	
Additional chemotherapy			
Yes	27 (69.2)	63 (64.9)	0.692*
No	12 (30.8)	34 (35.1)	
Type of cancer			
Breast cancer	13 (33.3)	32 (33.0)	0.386***
Prostate cancer	6 (15.4)	34 (35.1)	
Multiple myeloma	1 (2.6)	6 (6.2)	
Lung cancer	3 (7.7)	9 (9.3)	

Other	3 (7.7)	4 (4.1)	
Unknown	13 (33.3)	12 (12.4)	
Duration between tooth extraction and last denosumab injection			
Range (days)	1–283	2–272	
Mean ± SD	61.5 ± 53.1	84.6 ± 77.3	0.376**
Drug holiday before tooth extraction			
Yes	18 (46.2)	54 (55.7)	0.347*
No	21 (53.8)	43 (44.3)	
Reason of tooth extraction			
Periapical periodontitis	24 (61.5)	37 (38.1)	0.009***
Periapical periodontitis + radicular cyst	1 (2.6)	1 (1.0)	
P4 periodontitis	7 (18.0)	33 (34.0)	
C4 caries	1 (2.6)	17 (17.5)	
Pericoronitis	4 (10.3)	3 (3.1)	
Root fracture	1 (2.6)	6 (6.2)	
Other	1 (2.6)	0 (0)	
Periapical periodontitis			
Yes	25 (64.1)	38 (39.2)	0.014*
No	14 (35.9)	59 (60.8)	
P4 periodontitis			
Yes	7 (18.0)	33 (34.0)	0.095*
No	32 (82.0)	64 (66.0)	
Pericoronitis			
Yes	4 (10.3)	3 (3.1)	0.104*
No	35 (89.7)	94 (96.9)	
Jawbone			
Maxillary	16 (41.0)	54 (55.7)	0.134*
Mandibular	23 (59.0)	43 (44.3)	
Site of tooth extraction			
Anterior region	8 (20.5)	25 (25.8)	0.659*
Molar region	31 (79.5)	72 (74.2)	
Bone volume around tooth			
Adequate alveolar bone volume	26 (66.7)	49 (50.5)	0.127*
Bone loss	13 (33.3)	48 (49.5)	
Pre-existing inflammation			
Yes	38 (97.4)	65 (67.0)	< 0.001*
No	1 (2.6)	32 (33.0)	

Preoperative administration of antibiotics			
Yes	24 (61.5)	51 (52.6)	0.446*
No	15 (38.5)	46 (47.4)	
Number of teeth extracted			
Single	15 (38.5)	33 (34.0)	0.693*
Multiple	24 (61.5)	64 (66.0)	
Additional surgical procedure			
Bone removal			
Yes	17 (43.6)	30 (30.9)	0.169*
No	22 (56.4)	67 (69.1)	
Root amputation			
Yes	8 (20.5)	8 (8.2)	0.073*
No	31 (79.5)	89 (91.8)	
Wound status after extraction			
Open	17 (43.6)	33 (34.0)	0.297***
Closed with suture	20 (51.3)	51 (52.6)	
Completely closed with relaxation incision or removal of bone edge	2 (5.1)	13 (13.4)	

*Fisher's exact test, **Mann-Whitney *U* test, ***chi-squared test. DRONJ, denosumab-related osteonecrosis of the jaw; SD, standard deviation

Table 3. Results of multivariate logistic regression analysis of risk factors for denosumab-related osteonecrosis of the jaw

Variable	P-value	Odds ratio	95% CI	
			Lower	Upper
Pre-existing inflammation	0.001	243.77	11.03	5390.17
Steroid therapy	< 0.001	73.50	7.45	724.71
Periapical periodontitis	0.001	14.13	3.06	65.29
Longer duration of high-dose denosumab therapy	0.016	4.69	1.34	16.49
Female sex	0.037	1.04	1.00	1.09

CI, confidence interval

Fig. 1




Fig. 2

